All News

lung%2Cbright.jpg

Rheumatoid arthritis and lung disease in the spotlight at #ACR20

d Jeffrey Sparks

Rheumatoid arthritis (RA) has long been established to have pulmonary manifestations such as interstitial lung disease (ILD), and several research groups are pursuing this respiratory burden of RA at #ACR20. 

Read Article
Racial Disparities - Stroke, Heart Attacks Risks Higher in SLE: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #0433 presented Friday at #ACR20 annual meeting. https://t.co/Jx8hiPcNKA https://t.co/MvUj41KiuQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Read our news article "Ten-Year Analysis of Low-Dose Glucocorticoids in early RA" by Meral K. El Ramahi ( @MeralElRamahiMD) #ACR20. https://t.co/S9rOHc0864 https://t.co/6X4owP6pF0

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Mon

ACR20 - Day 4 Report

d Jack Cush, MD

Here are my highlights from day four, Monday, of the ACR 2020 Convergence. 



Vaccine Immunogenicity with Tofacitinib

Read Article
xray-of-hands-1526780.jpg

Erosions on X-ray: can we delegate this to the computers?

d David Liew, FRACP

The prospect of automating hand x-ray scoring reliably has always been an enticing one, and data presented at the American College of Rheumatology (ACR) Convergence 2020 suggest this might be in reach in the near future – opening up the prospect of automatic x-ray scoring

Read Article
Check out our article titled: Outcomes Switching to Monotherapy: SEAM-RA Trial by Dr. Eric Dein ( @ejdein1). #ACR20 https://t.co/0SKSzyH1yl https://t.co/6oqb1FfSX0

Links:

Dr. John Cush RheumNow ( View Tweet)
View our video on Abatacept in RA and ILD Patients with Dr Richard Conway ( @RichardPAConway) Dr. Richard Conway discusses abstract #0233 presented Friday at the #ACR20 virtual annual meeting. https://t.co/5zowsDetU1

Links:

Dr. John Cush RheumNow ( View Tweet)

computer screen safety

Ten-Year Analysis of Low-Dose Glucocorticoids in early RA

d Meral K. El Ramahi, MD, FACP, FACR

Abstract #1998 by C. Roubille et al from Montpellier, France is a 10-year prospective analysis that looked at the risk of severe outcomes related to very low-dose glucocorticoid in early rheumatoid arthritis from the ESPOIR cohort.

Read Article
Watch Dr. Janet Pope review abstracts #1198 and #1473 on lifestyle and risk of RA, lupus presented at the #ACR20 annual meeting. https://t.co/SAffgj4i5l https://t.co/VCpMbN3zmg

Links:

Dr. John Cush RheumNow ( View Tweet)
Roundup RHeum ACR

Rheumatology Round-Up with Drs. Kavanaugh & Cush

d Jack Cush, MD

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article
Tofa for RA by the grp of Dr. Atul Deodhar: >Tofa(56%) vs. pbo(29.4%)-significant improvement in ASAS20 at wk 16 >Primary & secondary endpts met >No new safety signals reported @Rheumnow #ACR20 https://t.co/G9U5cCQU7K
sheila RHEUMarampa ( View Tweet)
Dr. Jonathan Kay leads an international panel of rheumatologists to elicit their opinions on key abstracts at #ACR20. Panelists: @drdavidliew, @ejdein1, @MeralElRamahiMD, @RichardPAConway, @RHEUMarampa, and @jeffsparks https://t.co/btZKgwvoSn https://t.co/Okdvx9HuNc

Links:

Dr. John Cush RheumNow ( View Tweet)
What would you use in multidrug failure RA pt from last tweet +RF nodules & keratitis failed 2 TNFi & 2 JAKi @RheumNow #ACR20 @CRASCRRheum

Janet Pope Janetbirdope ( View Tweet)

Low-dose steroids in RA: what's the harm, right? (You probably know where I'm going with this) ESPOIR 10y data: total events, and severe infections worse with dose and time (cumulative 8.4g ≡ 5mg/d) No doubt some residual confounding, but real risk! #ACR20 ABST1998 @RheumNow https://t.co/BAQmOR1ped
David Liew drdavidliew ( View Tweet)
What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse. @RheumNow @CRASCRRheum https://t.co/9cTS1tNE42
Janet Pope Janetbirdope ( View Tweet)
Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in RA patients in sustained remission. 63% of tapered patients flared over 12 months vs 5% of maintained. Good response to reintroduction of TNFi @rheumnow #ACR20 Abstr#2010 https://t.co/Ki7PTsetbH
Richard Conway RichardPAConway ( View Tweet)
Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2.3). Unable to assess disease activity because claims database, but would imagine MTX grp more severe, driving increased VTE risk @RheumNow #ACR20 https://t.co/Z14xFTVXTp
Eric Dein ejdein1 ( View Tweet)
2020 #ACR20 RA guidelines were against steroid usage in RA. ESPOIR French cohort: 10 years of very low dose GC show increase events (death/CVD/fracture/severe ifn) even on low doses. HR increases every year. Cum GC dose-effect esp ifn, CVD. @RheumNow #ACRBest https://t.co/7b7chCPRxm
Eric Dein ejdein1 ( View Tweet)
Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadacitinib #JAKinhibitor -HZ events more common in patients taking 30mg vs 15mg -HZ more common in UPA vs those taking ADA+MTX & MTX Abs#2002 #ACR20 @RheumNow https://t.co/tQ03wBueW5

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Late breaking: in older #rheumatoidarthritis patients, those taking MTX have 2x risk of #VTE compared to those on HCQ. Important to consider #thromboembolic risk factors when starting new RA treatment. Abs#2000 #ACR20 @RheumNow https://t.co/lt8xDT4Ne8

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.